Sunday 18 October 2026
Export VNDA’s income statement to Excel — free account
Vanda Pharmaceuticals Inc.
VNDA Healthcare Biotechnology
Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.
4.03
0.21
−4.95%
Follow VNDA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.39 | 2.41 | 1.89 | 1.71 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.32) | (17.67) | (8.18) | (11.86) | |
P/B ratio |
0.63 | 1.59 | 1.46 | 1.67 | |
Price to Tangible BV |
0.83 | 2.47 | 2.48 | 3.44 | |
EV/Sales |
0.02 | 1.20 | 0.98 | 0.94 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.05) | (2.38) | (1.68) | (1.42) | |
EV/FCF |
(0.05) | (2.35) | (1.55) | (1.32) | |
Quick Ratio |
2.92 | 2.19 | 1.91 | 1.40 | |
Current Ratio |
3.12 | 2.39 | 2.16 | 1.61 | |
Net Debt/EBITDA |
9.25 | 7.48 | 4.24 | 2.77 | |
Debt/Assets |
0.47% | 0.83% | 0.87% | 0.77% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.34 | 0.38 | 0.41 | 0.42 | |
Operating CF/Net income |
1.40 | 0.21 | 1.03 | 0.50 | |
Capex/Depreciation |
1.02 | (0.02) | (3.01) | (0.05) | |
Research and Development Expense of Revenue |
40.11% | 50.70% | 54.98% | 73.13% | |
Selling, General and Administrative Expense of Revenue |
107.14% | 110.07% | 132.18% | 142.17% | |
Intangible Assets out of Total Assets |
0.18 | 0.24 | 0.27 | 0.27 | |
Share Based Compensation of Revenue |
3.75% | 3.99% | 4.96% | 4.17% | |
Graham Net Nets |
0.79 | 0.36 | 0.34 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(28.46%) | (42.29%) | (58.61%) | (75.65%) | |
Free Cash Flow Yield |
(28.13%) | (21.25%) | (33.42%) | (41.51%) | |
Revenue per Share |
0.95 | 0.97 | 0.87 | 0.84 | |
Operating CF per Share |
(0.54) | (0.50) | (0.84) | (0.52) | |
Capex per Share |
0.00 | 0.00 | (0.17) | 0.00 | |
Free Cash Flow per Share |
(0.54) | (0.50) | (1.02) | (0.52) | |
Cash per Share |
4.97 | 4.48 | 3.40 | 2.82 | |
Shareholders Equity per Share |
7.89 | 5.55 | 4.72 | 3.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.89 | 5.55 | 4.72 | 3.66 | |
Free Cash Flow |
(31.79) | (29.52) | (60.44) | (31.26) | |
Working Capital |
249.63 | 202.10 | 157.59 | 100.46 | |
Capital Expenditures |
(0.16) | (0.10) | (10.22) | (0.19) | |
Net Current Asset Value |
232.36 | 185.50 | 140.41 | 72.20 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.20 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
46.65 | 50.84 | 50.74 | 52.34 | |
Average Payables |
43.46 | 53.69 | 52.95 | 63.56 | |
Average Inventory |
1.83 | 1.79 | 1.81 | 1.92 | |
Average Assets |
623.13 | 572.58 | 532.73 | 518.61 | |
Average Common Equity |
503.61 | 432.87 | 396.09 | 353.26 |
Columns are period end dates